^
Association details:
| Biomarker: | EGFR exon 19 deletion + CCND1 overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
Published date:
10/19/2023
Excerpt:
Both PC9 and HCC827 cell lines have an exon 19 deletion in the EGFR gene....we tested the efficacy of the CDK4/6 inhibitor abemaciclib in the cell clones, combining a fixed dose (500 nM) of this drug with increasing concentrations of osimertinib....a short-term combined treatment inhibited cell proliferation more strongly than osimertinib alone in both PC9 and HCC827 Cyclin D1-overexpressing cells.
DOI:
https://doi.org/10.1007/s11523-023-01005-0
